Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 401 to 425 of 881

TitleReference numberPublishedLast updated
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA718
Secukinumab for treating active non-radiographic axial spondyloarthritisTA719
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA714
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillationTA249
Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA355
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillationTA256
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA275
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Ravulizumab for treating atypical haemolytic uraemic syndromeTA710
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitisTA708
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancerTA707
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapiesTA704
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692

Results per page

  1. 10
  2. 25
  3. 50
  4. All